Clinical Takeaway
People with PTSD who use cannabis respond just as well to trauma-focused therapies as those who do not use cannabis, even when a co-occurring substance use disorder is present. Trauma-focused treatment remains effective and should not be withheld based on cannabis use status.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether trauma-focused treatments maintain efficacy in the substantial proportion of PTSD patients who use cannabis, a question that has limited empirical guidance despite high comorbidity rates. The findings provide evidence-based guidance for treatment selection and outcome expectations when managing patients with co-occurring PTSD and cannabis use, potentially improving clinical decision-making and reducing unnecessary treatment discontinuation. Understanding differential treatment response in this population is essential given that cannabis use often complicates PTSD treatment engagement and outcomes in real-world clinical settings.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis addresses a clinically relevant question about trauma-focused treatment efficacy in cannabis-using patients with co-occurring PTSD and substance use disorders, several important limitations warrant careful interpretation. The analysis draws from only four of thirty-six available RCTs, which may not fully represent the broader evidence base and could introduce selection bias if included trials systematically differed from excluded ones in their handling of cannabis use. Additionally, cannabis use exists on a spectrum from occasional to dependent, and the abstraction does not clarify whether the analysis distinguished between these patterns or examined cannabis use as a potential mediator versus confounder of treatment response. Most pragmatically, clinicians should recognize that current evidence remains insufficient to categorically exclude cannabis users from evidence-based trauma-focused treatments like prolonged exposure or cognitive processing therapy, though baseline cannabis dependence may require additional concurrent substance use intervention and careful therapeutic monitoring to optimize outcomes.